Publication Name	World Journal of Hepatology
Manuscript ID	4587
Country	Thailand

Received	2013-07-09 08:11
Peer-Review Started	2013-07-09 09:25
First Decision by Editorial Office Director
Return for Revision	2013-07-29 12:01
Revised	2013-08-05 18:57
Publication Fee Transferred
Second Decision by Editor	2013-08-13 11:48
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-08-13 13:44
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-02 09:32
Publish the Manuscript Online	2013-10-01 17:51

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Hepatitis C genotype 6: A concise review and response-guided therapy proposal
Manuscript Source	Invited Manuscript
All Author List	Chalermrat Bunchorntavakul, Disaya Chavalitdhamrong and Tawesak Tanwandee
Funding Agency and Grant Number
Corresponding Author	Chalermrat Bunchorntavakul, MD, Assistant Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Rajavithi Road, Ratchathewi, Bangkok 10400, Thailand. dr.chalermrat@gmail.com
Key Words	Hepatitis C; Genotype 6; Epidemiology; Southeast Asia; Treatment; Pegylated interferon; Ribavirin; Response-guided therapy
Core Tip	Hepatitis C genotype 6 is endemic in Southeast Asia [prevalence varies between 10%-60% among all hepatitis C virus (HCV) infection], as well as also sporadically reported outside the area among immigrations. The diagnosis of HCV genotype can be inaccurate with earlier methods of genotyping due to identical 5’-UTR between genotype 6 and 1b, hence the newer genotyping methods with core sequencing are preferred. Risk factors and clinical course of HCV genotype 6 do not differ considerably from other genotypes. Treatment outcome of HCV genotype 6 with a combination of pegylated interferon and ribavirin is superior to genotype 1, and nearly comparable to genotype 3. Emerging data suggests that a shorter course 24-wk treatment is equally effective as a standard 48-wk treatment, particularly for those patients who attained undetectable HCV RNA at week 4.
Publish Date	2013-10-01 17:51
Citation	Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol 2013; 5(9): 496-504
URL	http://www.wjgnet.com/1948-5182/full/v5/i9/496.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i9.496

Full Article (PDF)	WJH-5-496.pdf
Manuscript File	4587-Review.doc
Answering Reviewers	4587-Answering reviewers.pdf
Copyright License Agreement	4587-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4587-Language certificate.pdf
Peer-review Report	4587-Peer reviews.pdf
Scientific Editor Work List	4587-Scientific editor work list.doc